These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 18174241)
21. Soluble transforming growth factor beta type II receptor attenuates TGF-beta1 activity in human colorectal cancer LoVo cells. Zhou R; Xiong B; Song H; Liu S; Wang X Oncol Rep; 2008 Dec; 20(6):1449-56. PubMed ID: 19020727 [TBL] [Abstract][Full Text] [Related]
22. Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells. Saito RA; Watabe T; Horiguchi K; Kohyama T; Saitoh M; Nagase T; Miyazono K Cancer Res; 2009 Apr; 69(7):2783-91. PubMed ID: 19293183 [TBL] [Abstract][Full Text] [Related]
23. Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells. Moodley R; Snyman C; Odhav B; Bhoola KD Biol Chem; 2005 Apr; 386(4):375-82. PubMed ID: 15899700 [TBL] [Abstract][Full Text] [Related]
24. L1 cell adhesion molecule promotes tumorigenicity and metastatic potential in non-small cell lung cancer. Hai J; Zhu CQ; Bandarchi B; Wang YH; Navab R; Shepherd FA; Jurisica I; Tsao MS Clin Cancer Res; 2012 Apr; 18(7):1914-24. PubMed ID: 22307136 [TBL] [Abstract][Full Text] [Related]
25. The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling. Lee JD; Hempel N; Lee NY; Blobe GC Carcinogenesis; 2010 Feb; 31(2):175-83. PubMed ID: 19955393 [TBL] [Abstract][Full Text] [Related]
26. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Muñoz NM; Upton M; Rojas A; Washington MK; Lin L; Chytil A; Sozmen EG; Madison BB; Pozzi A; Moon RT; Moses HL; Grady WM Cancer Res; 2006 Oct; 66(20):9837-44. PubMed ID: 17047044 [TBL] [Abstract][Full Text] [Related]
27. miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Sun Y; Bai Y; Zhang F; Wang Y; Guo Y; Guo L Biochem Biophys Res Commun; 2010 Jan; 391(3):1483-9. PubMed ID: 20034472 [TBL] [Abstract][Full Text] [Related]
28. Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta. Hempel N; How T; Cooper SJ; Green TR; Dong M; Copland JA; Wood CG; Blobe GC Carcinogenesis; 2008 May; 29(5):905-12. PubMed ID: 18299279 [TBL] [Abstract][Full Text] [Related]
29. HOXB2, an adverse prognostic indicator for stage I lung adenocarcinomas, promotes invasion by transcriptional regulation of metastasis-related genes in HOP-62 non-small cell lung cancer cells. Inamura K; Togashi Y; Ninomiya H; Shimoji T; Noda T; Ishikawa Y Anticancer Res; 2008; 28(4B):2121-7. PubMed ID: 18751384 [TBL] [Abstract][Full Text] [Related]
30. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo. Katiyar SK; Meeran SM; Katiyar N; Akhtar S Mol Carcinog; 2009 Jan; 48(1):24-37. PubMed ID: 18459128 [TBL] [Abstract][Full Text] [Related]
31. Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth. Mao X; Seidlitz E; Truant R; Hitt M; Ghosh HP Oncogene; 2004 Jul; 23(33):5632-42. PubMed ID: 15184878 [TBL] [Abstract][Full Text] [Related]
32. The cytoplasmic domain is critical to the tumor suppressor activity of TSLC1 in non-small cell lung cancer. Mao X; Seidlitz E; Ghosh K; Murakami Y; Ghosh HP Cancer Res; 2003 Nov; 63(22):7979-85. PubMed ID: 14633730 [TBL] [Abstract][Full Text] [Related]
33. Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth. Gatza CE; Holtzhausen A; Kirkbride KC; Morton A; Gatza ML; Datto MB; Blobe GC Neoplasia; 2011 Aug; 13(8):758-70. PubMed ID: 21847367 [TBL] [Abstract][Full Text] [Related]
34. Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer. Sakaguchi J; Kyo S; Kanaya T; Maida Y; Hashimoto M; Nakamura M; Yamada K; Inoue M Gynecol Oncol; 2005 Sep; 98(3):427-33. PubMed ID: 15993480 [TBL] [Abstract][Full Text] [Related]
35. Upregulated fascin1 in non-small cell lung cancer promotes the migration and invasiveness, but not proliferation. Zhao J; Zhou Y; Zhang Z; Tian F; Ma N; Liu T; Gu Z; Wang Y Cancer Lett; 2010 Apr; 290(2):238-47. PubMed ID: 19819618 [TBL] [Abstract][Full Text] [Related]
36. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Zhang W; Chen Y; Wei H; Zheng C; Sun R; Zhang J; Tian Z Clin Cancer Res; 2008 Oct; 14(20):6432-9. PubMed ID: 18927282 [TBL] [Abstract][Full Text] [Related]
37. Loss of H-cadherin protein expression in human non-small cell lung cancer is associated with tumorigenicity. Zhong Y; Delgado Y; Gomez J; Lee SW; Perez-Soler R Clin Cancer Res; 2001 Jun; 7(6):1683-7. PubMed ID: 11410507 [TBL] [Abstract][Full Text] [Related]
38. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results. Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205 [TBL] [Abstract][Full Text] [Related]
39. Roles for the type III TGF-beta receptor in human cancer. Gatza CE; Oh SY; Blobe GC Cell Signal; 2010 Aug; 22(8):1163-74. PubMed ID: 20153821 [TBL] [Abstract][Full Text] [Related]
40. IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. Ho MY; Leu SJ; Sun GH; Tao MH; Tang SJ; Sun KH J Immunol; 2009 Nov; 183(10):6217-26. PubMed ID: 19841177 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]